The Technical Analyst
ImmunoPrecise Antibodies [IPA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
ImmunoPrecise Antibodies Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.81% $1.230
America/New_York / 19 apr 2024 @ 14:54
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 32.37 mill |
| EPS: | -0.470 |
| P/E: | -2.62 |
| Earnings Date: | Jul 05, 2024 |
| SharesOutstanding: | 26.32 mill |
| Avg Daily Volume: | 0.606 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.62 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.45x |
| Company: PE -2.62 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.053 - 1.407 ( +/- 14.39%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2008-12-12 | Aisling Capital Ii Lp | Buy | 861 826 | Convertible 12% Note Due 2009 |
| 2008-12-12 | Aisling Capital Ii Lp | Buy | 10 412 | Series D-1 Convertible Preferred Stock |
| 2008-12-12 | Aisling Capital Ii Lp | Buy | 1 | Warrant (right to buy) |
| 2008-12-12 | Aisling Capital Ii Lp | Buy | 1 | Warrant (right to buy) |
| 2008-12-12 | Aisling Capital Ii Lp | Sell | 10 000 | Series C-1 Convertible Preferred Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 20 transactions |
| Buy: 4 917 425 | Sell: 9 058 105 |
Forecast:
16:00 - $1.240
Live Trading Signals (every 1 min)
Forecast
1: 15:16 - $1.243
Forecast 2: 16:00 - $1.240
Forecast 3: 16:00 - $1.240
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.230 (-0.81% ) |
| Volume | 0.0986 mill |
| Avg. Vol. | 0.606 mill |
| % of Avg. Vol | 16.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IPA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IPA
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Latest Press Releases
2024-04-12 09:00:00 - Press Release
Immunoprecise Antibodies And Intersystems Partner To Leverage Ai In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
Victoria, bc / accesswire/ april 12, 2024 / intersystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability and speed challenges partnered with immunoprecise antibodies (nasdaq:ipa) ("ipa"), an artificial intelligence-driven biotherapeutic research and technology company in what they stated is a landmark collaboration. featured photo by cdc on unsplash.
2024-03-28 07:02:00 - Press Release
Intersystems And Ipa's Subsidiary Biostrand Collaborate To Unveil The Innovative Integration Of Vector Search With Lensai For Ai-driven Healthcare Applications
Victoria, british columbia--(business wire)---- $ipa #ai--ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), intersystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with immunoprecise antibodies ltd. (ipa) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce a landmark collaboration. this collaboration i.
2024-03-20 07:02:00 - Press Release
Ipa Acquires The Carterra Lsa® Instrument To Enhance Antibody Discovery And Bolster Its Ai Developments
Victoria, british columbia--(business wire)---- $ipa #ai--ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the lsa® instrument platform from carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. this instrument allows for high throughput surface plasmon resonance-based antibody characterizations thereby.
2024-03-14 08:05:00 - Press Release
Ipa Reports Financial Results And Recent Business Highlights For Third Quarter Fiscal Year 2024*
Victoria, british columbia--(business wire)---- $ipa #ai--ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its third quarter of the 2024 fiscal year (“fy24”), which ended january 31, 2024. “immunoprecise antibodies proudly reports a fourth consecutive quarter of record revenue, demonstrating our capability to fulfill the rising needs of both new and existing clien.
2024-03-08 08:30:00 - Press Release
Immunoprecise Antibodies (nasdaq:ipa) Subsidiary Biostrand Introduces Breakthrough Ai Model In Life Sciences, Harnessing Llm Stacking And Hyft Technology
Victoria, bc / accesswire / march 8, 2024 / anyone familiar with the intricacies of life science knows how truly complicated dna is; without a full understanding of the language of dna, scientists are often at a standstill when it comes to advanced medicine. that's why the work of companies like immunoprecise antibodies (nasdaq:ipa) ("ipa") is important to identifying, preventing and treating diseases.
Latest News
2024-03-14 14:49:13 - Seeking Alpha
ImmunoPrecise Antibodies Ltd. (IPA) Q3 2024 Earnings Call Transcript
2024-03-14 10:30:30 - Zacks Investment Research
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates
ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate.
2024-02-07 07:26:04 - Zacks Investment Research
New Strong Buy Stocks for February 7th
AMSC, META, CLX, IPA and KMPR have been added to the Zacks Rank #1 (Strong Buy) List on February 7, 2023.
2024-02-05 07:41:04 - Zacks Investment Research
New Strong Buy Stocks for February 5th
EZPW, MOD, IPA, WDC and OSK have been added to the Zacks Rank #1 (Strong Buy) List on February 5, 2023.
2023-12-07 09:00:00 - Accesswire
ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14
VICTORIA, BC / ACCESSWIRE / December 7, 2023 / ImmunoPrecise Antibodies (NASDAQ:IPA) ("IPA"), a leading company in AI-driven biotherapeutic research and technology, has recently announced important changes to its Board of Directors and upcoming financial reporting activities. At its recent Annual General Meeting, the company welcomed Mitch Levine to its Board of Directors, which was followed soon thereafter by his appointment as the Chairman of the Board.
2023-12-06 09:00:14 - InvestorPlace
Why Is ImmunoPrecise Antibodies (IPA) Stock Down 39% Today?
ImmunoPrecise Antibodies (NASDAQ: IPA ) stock is falling hard on Wednesday after the biotherapeutic company priced its shares in a public offering. This has ImmunoPrecise Antibodies offering 1.1 million shares of IPA stock for $1 per share.
2023-10-23 08:16:22 - Zacks Investment Research
New Strong Buy Stocks for October 23rd
MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.
2023-09-08 08:30:00 - Business Wire
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2024, on Thursday, September 14, 2023, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will ho.
2023-07-07 14:25:25 - Seeking Alpha
ImmunoPrecise Antibodies Ltd. (IPA) Q4 2023 Earnings Call Transcript
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q4 2023 Earnings Conference Call July 7, 2023 10:30 AM ET Company Participants Jennifer Bath - CEO Barry Duplantis - VP-Client Relations Ilse Roodink - Chief Scientific Officer Brad McConn - CFO Conference Call Participants Will McHale - Ingalls & Snyder Ramakanth Swayampakula - H.C.
2023-05-17 08:04:00 - Business Wire
IPA to Present at Jefferies Healthcare Conference 2023
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced that Dr. Jennifer Bath, the company's Chief Executive Officer and President, will present at the Jefferies Healthcare Conference on Friday June 9, 2023, at 11:00 a.m. Eastern time. The live and archived webcast of the presentation will be accessible from the company's website at https://ir.